Stay updated on Pembrolizumab in SCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in SCLC Clinical Trial page.

Latest updates to the Pembrolizumab in SCLC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedRevision v3.4.2 was added and v3.4.1 was removed.SummaryDifference0.1%

- Check19 days agoChange DetectedRevision label updated from v3.4.0 to v3.4.1; no changes to study details or content are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check27 days agoChange DetectedThe changes are minor UI and metadata updates, including a glossary toggle, updated QC criteria wording, capitalization adjustments for No FEAR Act data, and a new revision tag (v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check41 days agoChange DetectedRevision: v3.3.4 was added and v3.3.3 was removed from the page. This is a minor maintenance update that does not alter study content or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check62 days agoChange Detected- Locations: New York added as a study site. - Deletions: HHS Vulnerability Disclosure and New York Locations removed; revision updated from v3.3.2 to v3.3.3.SummaryDifference0.2%

- Check91 days agoChange DetectedRevision tag updated from v3.2.0 to v3.3.2. This appears to be a minor version update with no impact on study content.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in SCLC Clinical Trial page.